Our study demonstrated that the novel SCD1 inhibitor E6446 suppressed two key processes of NAFLD development (hepatic lipogenesis and adipogenic differentiation) via SCD1-ATF3 signaling (Fig. 8). This evidence concerns the gene ATF3 and metabolic dysfunction-associated steatotic liver disease.